# Treatment approaches for ANCA-associated vasculitis
The treatment of ANCA-associated vasculitis is aimed at suppressing inflamed blood vessels and preventing organ damage. The choice of treatment depends on the severity of the disease, which organs are involved, and whether this is the first occurrence or a recurrence of the disease.
Immunosuppressive medications (anti-inflammatory agents)
Corticosteroids
ProveniIncluded in official guidelines, or approved by EMA or FDA
Corticosteroids (for example prednisone or methylprednisolone) work by suppressing the function of the immune system and combating inflammation. They are especially used at the beginning of treatment, sometimes in high doses to quickly bring the disease under control. Later, the dose is usually gradually reduced as the disease becomes quieter.
Common side effects include sleep problems, increased appetite, mood swings, elevated blood levels and muscle weakness. With longer use, dental problems, bone loss and increased risk of infection can occur. These are reasons why doctors try to keep the dose as low as possible in the long term or even discontinue it altogether.
Rituximab
ProveniIncluded in official guidelines, or approved by EMA or FDA
Rituximab is a biological medication that destroys B-cells (certain immune cells) involved in the inflammation. It is used in patients with severe ANCA-associated vasculitis, especially if the lungs or kidneys are affected. It can be given both as an injection under the skin and as an infusion.
Known side effects include reactions at the infusion site, fever, headache and increased risk of infection, especially in the first weeks after treatment. Tuberculosis can also become active again in patients who have had this disease before. Biosimilars (generic versions of the same medication) are now also available and appear to be similarly effective.
Cyclophosphamide
ProveniIncluded in official guidelines, or approved by EMA or FDA
Cyclophosphamide is a potent immunosuppressive agent that combats inflammatory cells by damaging their ability to divide. It is especially used in very severe forms of vasculitis, especially with lung or kidney damage. It is usually given as an infusion, followed by rituximab or other medications to maintain long-term effect.
This medication carries significant risks: serious risk of infection, lung fibrosis (scarring of lung tissue), bladder inflammation, fertility problems and very low blood cell counts. For this reason, it is carefully monitored and usually used for a limited time.
Mycophenolate mofetil and azathioprine
ProveniIncluded in official guidelines, or approved by EMA or FDA
These medications also work by restraining immune cells, but at a different biological level than cyclophosphamide. They are especially used to maintain remission (period of disease inactivity) after initiation with stronger medications, or in less severe forms.
Side effects are generally milder than with cyclophosphamide: stomach complaints, fatigue, blood cell decreases and infections occur less frequently. Some women may experience pregnancy complications with azathioprine.
Complement inhibitors
Avacopan
ProveniIncluded in official guidelines, or approved by EMA or FDA
Avacopan blocks complement, a component of the natural immune system that plays a role in ANCA-associated vasculitis. It is given as tablets and works directly against the inflammatory mechanisms without suppressing general immunity.
Side effects are relatively mild and mainly involve stomach complaints, headache and upper respiratory tract infections. This medication is available in oral form (tablets), which makes its use easier than infusions.
Monitoring and supportive care
Blood tests
ProveniIncluded in official guidelines, or approved by EMA or FDA
Regular blood draws monitor how well the treatment is working (by looking at ANCA antibodies), whether inflammation is decreasing and how blood cell counts, liver and kidney function are doing. This helps doctors adjust the dose and detect side effects early.
Imaging
ProveniIncluded in official guidelines, or approved by EMA or FDA
CT scans of the chest, abdomen, or nerves can show which organs are involved and how well they are healing. This is usually done at the beginning and again later when doctors know how well the treatment is working or if new symptoms appear.
Medications to prevent side effects
Infection prevention
ProveniIncluded in official guidelines, or approved by EMA or FDA
Because immunosuppressive medications increase infection risk, many patients receive preventive medications against certain infections (such as Pneumocystis pneumonia) and sometimes vaccinations before they start. This is standard practice for severe vasculitis.
Bone protectors
ProveniIncluded in official guidelines, or approved by EMA or FDA
In patients who use corticosteroids long-term, medications are sometimes given to prevent bone loss, for example calcium supplements and vitamin D. This prevents osteoporosis.
Treatment of specific organ damage
Severe lung bleeding (diffuse alveolar hemorrhage)
ProveniIncluded in official guidelines, or approved by EMA or FDA
For bleeding in the lungs, rapid, intensive immunosuppression is started, and sometimes plasmapheresis (blood plasma purification) is used. This is an acute situation that requires hospitalization.
Kidney disease (glomerulonephritis)
ProveniIncluded in official guidelines, or approved by EMA or FDA
For kidney damage from vasculitis, combined use of corticosteroids and rituximab or cyclophosphamide is usually given, with the aim of preserving kidney function and preventing further damage.
Experimental and investigational treatments
NKX019
ExperimentaliOngoing in study setting, outcome still unknown
NKX019 is a new biological agent that targets certain B cells and is currently being studied in clinical trials for ANCA-associated vasculitis. Results from these trials are not yet available for general use.
Obinutuzumab
ResearchediPositive results in clinical studies, not yet standard treatment
Obinutuzumab also works on B cells and studies are testing whether it works as well as or better than standard treatments for newly developed kidney damage when combined with low-dose corticosteroids.
---
_This information never replaces a doctor's judgment. Always discuss your situation with your own healthcare provider._